BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1269 related articles for article (PubMed ID: 26179059)

  • 21. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
    Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
    Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of adjuvant radiotherapy in FIGO stage IIIC endometrial carcinoma: Treatment outcomes and prognostic factors in 52 irradiated patients.
    Hsieh HY; Wang L; Lu CH; Lin JC; Chen CC
    J Formos Med Assoc; 2018 Jul; 117(7):613-620. PubMed ID: 28867455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
    Onal C; Sari SY; Yildirim BA; Yavas G; Gultekin M; Guler OC; Akyurek S; Yildiz F
    J Gynecol Oncol; 2019 May; 30(3):e28. PubMed ID: 30887753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?
    Crosby MA; Tward JD; Szabo A; Lee CM; Gaffney DK
    Am J Clin Oncol; 2010 Aug; 33(4):364-9. PubMed ID: 20689365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
    Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
    Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
    Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
    Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
    Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
    BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
    Hoekstra AV; Kim RJ; Small W; Rademaker AW; Helenowski IB; Singh DK; Schink JC; Lurain JR
    Gynecol Oncol; 2009 Aug; 114(2):273-8. PubMed ID: 19428094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of FIGO Stage IIIc endometrial cancer patients.
    McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
    Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.
    Alektiar KM; McKee A; Venkatraman E; McKee B; Zelefsky MJ; Mychalczak BR; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):707-13. PubMed ID: 12062616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer.
    Lum MM; Belnap TW; Frandsen J; Brown AP; Sause WT; Soisson AP; Dodson MK; Werner T; Gaffney DK
    Am J Clin Oncol; 2015 Jun; 38(3):283-8. PubMed ID: 23774072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [High dose rate vaginal brachytherapy in endometrial cancer after surgery].
    Moreau-Claeys MV; Brunaud C; Hoffstetter S; Buchheit I; Peiffert D
    Cancer Radiother; 2011 Jun; 15(3):169-75. PubMed ID: 21237693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival.
    Ly D; Rowley BD; Dodson MK; Soisson PA; Jolles CJ; Gaffney DK; Sause WT
    Gynecol Oncol; 2014 May; 133(2):250-5. PubMed ID: 24589416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
    Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
    Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A; Topfedaisi Ozkan N; Öz M; Kimyon Comert G; Firat Cuylan Z; Çoban G; Turkmen O; Erdem B; Şahin H; Akbayır Ö; Dede M; Turan AT; Celik H; Güngör T; Haberal A; Arvas M; Meydanli MM
    J Gynecol Oncol; 2018 Jul; 29(4):e48. PubMed ID: 29770619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
    Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
    J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.